



Sanofi announces the next steps of its Research site in Toulouse, France

Paris, France - May 17, 2013 - Today, the French ministerial mission presented the conclusions of its report regarding the Sanofi Research site in Toulouse, France.

The report confirms the necessity to reorganize Sanofi's Research in France, in particular to address its structural weaknesses and to open the Group to the external collaborations. This evolution is essential for the discovery of new medicines, to create an environment for long-term growth and to ensure the sustainability of the Group, especially its 26 industrial sites in France.

Consequently, Sanofi confirms its intent to regroup its research activities in France in the regions of Paris and Lyon, in Strasbourg and to transform the Montpellier R&D site into a strategic Development center for the Group.

The report provides a road map to transform the structures of the site in Toulouse, so that it keeps a scientific and technological mission, and to safeguard a maximum number of jobs in the region. Based on the options considered in the report, Sanofi will explore the following:

- The creation of a technological platform to provide services for Sanofi and other biotechnological or pharmaceutical companies;
- The spin-off of activities dedicated to the development of innovative therapeutic solutions;
- The establishment of local start-ups on the site.

Sanofi commits during the next five years to accompany the transition of these new autonomous structures, while respecting tradition and social practices.

In addition, as already announced, the anti-infectious research of the site will be moved to Lyon, where Sanofi plans to create a global center of excellence.

These proposals are now going to be developed thoroughly with the social partners, also supported by working groups in Toulouse to prepare for the evolution of the site and to define the ways to support those new structures.

With the definition of its new model, Sanofi confirms its commitment to Research in France, where the Group employs 50 % of its global R&D workforce, in order to create a successful and dynamic research necessary for its future.



About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Jean-Marc Podvin
Tel.: + (33) 1 53 77 46 46
mr@sanofi.com

Investor Relations

Sébastien Martel
Tel.: + (33) 1 53 77 45 45
ir@sanofi.com